KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Cash: 2020-2025

Historic Change in Cash for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to -$9.3 million.

  • AbCellera Biologics' Change in Cash rose 57.19% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.5 million, marking a year-over-year increase of 5.02%. This contributed to the annual value of $23.0 million for FY2024, which is 109.06% up from last year.
  • Per AbCellera Biologics' latest filing, its Change in Cash stood at -$9.3 million for Q3 2025, which was up 86.12% from -$66.8 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Change in Cash high stood at $245.8 million for Q2 2022, and its period low was -$417.4 million during Q3 2022.
  • For the 3-year period, AbCellera Biologics' Change in Cash averaged around -$27.7 million, with its median value being -$9.7 million (2024).
  • Over the last 5 years, AbCellera Biologics' Change in Cash had its largest YoY gain of 341.35% in 2021, and its largest YoY loss of 1,146.27% in 2021.
  • Over the past 5 years, AbCellera Biologics' Change in Cash (Quarterly) stood at -$16.6 million in 2021, then soared by 187.98% to $14.6 million in 2022, then crashed by 368.51% to -$39.1 million in 2023, then skyrocketed by 175.92% to $29.7 million in 2024, then spiked by 57.19% to -$9.3 million in 2025.
  • Its Change in Cash was -$9.3 million in Q3 2025, compared to -$66.8 million in Q2 2025 and $2.9 million in Q1 2025.